{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:00:11Z","timestamp":1793660411563,"version":"4.5.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.vaccine.2019.12.058","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T08:31:03Z","timestamp":1578645063000},"page":"1678-1689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Persistence of vaccine-elicited immune response up to 14\u00a0years post-HIV gp120-NefTat\/AS01B vaccination"],"prefix":"10.1016","volume":"38","author":[{"given":"Olivier","family":"Van Der Meeren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Jongert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"Seaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marguerite","family":"Koutsoukos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"Aerssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Brackett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Debois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Janssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Leroux-Roels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Mesia Vela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheetal","family":"Sawant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole L.","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia D.","family":"Tomaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Leroux-Roels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.12.058_b0005","unstructured":"World Health Organization. Data on the size of the HIV\/AIDS epidemic 2018. http:\/\/apps.who.int\/gho\/data\/view.main.22100WHO?lang=en [last accessed August 22, 2019]."},{"key":"10.1016\/j.vaccine.2019.12.058_b0010","unstructured":"World Health Organization. HIV vaccine development. http:\/\/www.who.int\/immunization\/research\/development\/hiv_vaccdev\/en\/ [last accessed August 22, 2019]."},{"key":"10.1016\/j.vaccine.2019.12.058_b0015","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.12.058_b0020","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1473-3099(12)70088-9","article-title":"Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B\/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144","volume":"12","author":"Robb","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.058_b0025","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.cell.2015.10.027","article-title":"Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology","volume":"163","author":"Chung","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2019.12.058_b0030","doi-asserted-by":"crossref","first-page":"e75665","DOI":"10.1371\/journal.pone.0075665","article-title":"Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial","volume":"8","author":"Gottardo","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.12.058_b0035","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1146\/annurev-med-052912-123749","article-title":"Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection","volume":"66","author":"Kim","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.vaccine.2019.12.058_b0040","doi-asserted-by":"crossref","first-page":"e0180720","DOI":"10.1371\/journal.pone.0180720","article-title":"V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144","volume":"12","author":"Perez","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.12.058_b0045","doi-asserted-by":"crossref","first-page":"9019","DOI":"10.1073\/pnas.1301456110","article-title":"Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG","volume":"110","author":"Tomaras","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2019.12.058_b0050","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/imr.12514","article-title":"Complex immune correlates of protection in HIV-1 vaccine efficacy trials","volume":"275","author":"Tomaras","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2019.12.058_b0055","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.12.058_b0060","doi-asserted-by":"crossref","first-page":"228ra39","DOI":"10.1126\/scitranslmed.3007730","article-title":"Vaccine-induced Env V1\u2013V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination","volume":"6","author":"Yates","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2019.12.058_b0065","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nbt.3187","article-title":"COMPASS identifies T-cell subsets correlated with clinical outcomes","volume":"33","author":"Lin","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2019.12.058_b0070","doi-asserted-by":"crossref","first-page":"310rv7","DOI":"10.1126\/scitranslmed.aac7732","article-title":"Immune correlates of vaccine protection against HIV-1 acquisition","volume":"7","author":"Corey","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2019.12.058_b0075","doi-asserted-by":"crossref","first-page":"e87572","DOI":"10.1371\/journal.pone.0087572","article-title":"Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection","volume":"9","author":"Zolla-Pazner","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.12.058_b0080","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1016\/S2352-3018(18)30071-7","article-title":"Subtype C ALVAC-HIV and bivalent subtype C gp120\/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1\/2 trial","volume":"5","author":"Bekker","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.vaccine.2019.12.058_b0085","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(18)31364-3","article-title":"Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1\/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13\u201319)","volume":"392","author":"Barouch","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.12.058_b0090","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1128\/JVI.77.2.1049-1058.2003","article-title":"Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine","volume":"77","author":"Voss","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.12.058_b0095","doi-asserted-by":"crossref","first-page":"7016","DOI":"10.1016\/j.vaccine.2010.08.035","article-title":"Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems","volume":"28","author":"Leroux-Roels","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.058_b0100","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01843-17","article-title":"HIV-1 envelope glycoproteins from diverse clades differentiate antibody responses and durability among vaccinees","volume":"92","author":"Yates","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.12.058_b0105","doi-asserted-by":"crossref","first-page":"12449","DOI":"10.1128\/JVI.01708-08","article-title":"Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia","volume":"82","author":"Tomaras","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.12.058_b0110","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1097\/QAD.0b013e32834b348e","article-title":"Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection","volume":"25","author":"Yates","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.vaccine.2019.12.058_b0115","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/1471-2105-14-145","article-title":"Quality control, analysis and secure sharing of Luminex\u00ae immunoassay data using the open source LabKey Server platform","volume":"14","author":"Eckels","year":"2013","journal-title":"BMC Bioinf"},{"key":"10.1016\/j.vaccine.2019.12.058_b0120","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.immuni.2012.11.011","article-title":"Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2","volume":"38","author":"Liao","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2019.12.058_b0125","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1198\/sbr.2009.0008","article-title":"Simultaneous evaluation of the magnitude and breadth of a left and right censored multivariate response, with application to HIV vaccine development","volume":"1","author":"Huang","year":"2009","journal-title":"Stat Biopharm Res"},{"key":"10.1016\/j.vaccine.2019.12.058_b0130","unstructured":"The R Foundation. The R project for statistical computing. http:\/\/www.r-project.org\/ [last accessed August 22, 2019]."},{"key":"10.1016\/j.vaccine.2019.12.058_b0135","doi-asserted-by":"crossref","first-page":"15614","DOI":"10.1073\/pnas.1413550111","article-title":"Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development","volume":"111","author":"Lewis","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2019.12.058_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/aid.2011.0053","article-title":"How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?","volume":"28","author":"Klasse","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.vaccine.2019.12.058_b0145","doi-asserted-by":"crossref","first-page":"e1005817","DOI":"10.1371\/journal.ppat.1005817","article-title":"Antibody-mediated internalization of infectious HIV-1 virions differs among antibody isotypes and subclasses","volume":"12","author":"Tay","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2019.12.058_b0150","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.chom.2015.03.002","article-title":"Passively acquired antibody-dependent cellular cytotoxicity (ADCC) activity in HIV-infected infants is associated with reduced mortality","volume":"17","author":"Milligan","year":"2015","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2019.12.058_b0155","doi-asserted-by":"crossref","first-page":"11521","DOI":"10.1128\/JVI.01023-12","article-title":"Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family","volume":"86","author":"Bonsignori","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.12.058_b0160","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02325-16","article-title":"Monoclonal antibodies specific for the V2, V3, CD4-binding Site, and gp41 of HIV-1 mediate phagocytosis in a dose-dependent manner","volume":"91","author":"Musich","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.12.058_b0165","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1084\/jem.20041270","article-title":"Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells","volume":"200","author":"Lichterfeld","year":"2004","journal-title":"J Exp Med"},{"issue":"11","key":"10.1016\/j.vaccine.2019.12.058_b0170","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/infdis\/jiz008","article-title":"Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period","volume":"219","author":"Spearman","year":"2019","journal-title":"J Infect"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19317220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19317220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:40:32Z","timestamp":1759401632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19317220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0264410X19317220"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.058","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistence of vaccine-elicited immune response up to 14\u00a0years post-HIV gp120-NefTat\/AS01B vaccination","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}